| Index | — | P/E | — | EPS (ttm) | -0.04 | Insider Own | 8.36% | Shs Outstand | 201.52M | Perf Week | -0.42% |
| Market Cap | 475.60M | Forward P/E | — | EPS next Y | -0.01 | Insider Trans | -1.70% | Shs Float | 190.68M | Perf Month | 3.51% |
| Enterprise Value | 493.60M | PEG | — | EPS next Q | — | Short Float | 8.72% | Perf Quarter | 7.76% | ||
| Income | -7.00M | P/S | 2.14 | EPS this Y | — | Short Ratio | 7.67 | Perf Half Y | -13.24% | ||
| Sales | 222.00M | P/B | 6.70 | EPS next Y | — | ROA | -3.31% | Short Interest | 16.63M | Perf YTD | 14.56% |
| Book/sh | 0.35 | P/C | 8.49 | EPS next 5Y | — | ROE | -10.31% | 52W High | 3.47 -32.56% | Perf Year | 68.57% |
| Cash/sh | 0.28 | P/FCF | — | EPS past 3/5Y | — | ROIC | -1.06% | 52W Low | 1.38 69.57% | Perf 3Y | 81.54% |
| Dividend Est. | — | EV/EBITDA | 164.53 | Sales past 3/5Y | 8.34% 17.49% | Gross Margin | 52.05% | Volatility | 4.53% 3.93% | Perf 5Y | -62.24% |
| Dividend TTM | — | EV/Sales | 2.22 | EPS Y/Y TTM | — | Oper. Margin | -0.73% | ATR (14) | 0.10 | Perf 10Y | -54.17% |
| Dividend Ex-Date | — | Quick Ratio | 1.07 | Sales Y/Y TTM | 15.63% | Profit Margin | -3.06% | RSI (14) | 49.01 | Recom | 2.20 |
| Dividend Gr. 3/5Y | — | Current Ratio | 1.83 | EPS Q/Q | — | SMA20 | 2.08% | Beta | 1.81 | Target Price | 4.00 |
| Payout | 0.00% | Debt/Eq | 1.04 | Sales Q/Q | 9.62% | SMA50 | -4.03% | Rel Volume | 2.00 | Prev Close | 2.36 |
| Employees | 268 | LT Debt/Eq | 0.62 | Earnings | Mar 01 | SMA200 | -3.57% | Avg Volume | 1.94M | Price | 2.34 |
| IPO Date | Jan 31, 1997 | Option/Short | No / Yes | EPS/Sales Surpr. | 25.00% 0.64% | Net Debt/EBITDA | 6.00 | Volume | 3,887,997 | Change | -0.85% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-01-26 | Upgrade | BTIG | Neutral → Buy | $4.00 |
| Oct-17-24 | Reiterated | Stifel Nicolaus | $3.00 | |
| May-03-24 | Reiterated | Cantor Fitzgerald | Overweight | $4.00 |
| Apr-12-24 | Reiterated | Craig-Hallum | $5.00 | |
| Jan-20-23 | Downgrade | BTIG | Buy → Neutral | |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy | |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 222 | 206 | 180 | 156 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 107 | 94 | 81 | 70 | — | — | — | — | — | |
| Gross Profit | 116 | 112 | 100 | 86 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 83 | 81 | 76 | 76 | — | — | — | — | — | |
| Research and Development | 61 | 68 | 59 | 68 | — | — | — | — | — | |
| Other Operating Expense | -28 | -28 | -21 | -28 | — | — | — | — | — | |
| Operating Income | -2 | -9 | -14 | -30 | — | — | — | — | — | |
| Interest Expense | 8 | 8 | 9 | 8 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 4 | 2 | 2 | 1 | — | — | — | — | — | |
| Net Income Before Taxes | -7 | -15 | -21 | -37 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -7 | -16 | -21 | -37 | — | — | — | — | — | |
| Net Income From Continuing Operations | -7 | -16 | -21 | -38 | — | — | — | — | — | |
| Net Income | -7 | -16 | -21 | -37 | — | — | — | — | — | |
| EPS (Recurring) | -0.04 | -0.08 | -0.11 | -0.21 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.04 | -0.08 | -0.11 | -0.21 | — | — | — | — | — | |
| EPS (Diluted) | -0.04 | -0.08 | -0.11 | -0.21 | — | — | — | — | — | |
| EBITDA | 3 | -6 | -10 | -26 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.12 | 1.91 | 1.58 | 2.49 | — | — | — | — | — | |
| Gross Margin | 52.25 | 54.37 | 55.56 | 55.13 | — | — | — | — | — | |
| Operating Margin | -0.90 | -4.37 | -7.78 | -19.23 | — | — | — | — | — | |
| Net Margin | -3.15 | -7.77 | -11.67 | -23.72 | — | — | — | — | — | |
| Shares Outstanding | 201 | 191 | 185 | 180 | — | — | — | — | — | |
| Market Capitalization | 470 | 393 | 285 | 389 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Jensen Chrystal | Chief Legal Officer | Aug 17 '26 | Sale | 2.98 | 30,000 | 89,529 | 936,657 | Aug 17 |
| Jayaraman Vivek K | Chief Executive Officer | Jul 16 '26 | Sale | 3.16 | 16,666 | 52,665 | 2,232,211 | Jul 20 |
| Jayaraman Vivek K | Chief Operating Officer | Jun 30 '26 | Sale | 2.94 | 42,359 | 124,658 | 1,694,348 | Jul 02 |
| Jensen Chrystal | Chief Legal Officer | Jun 30 '26 | Sale | 2.94 | 24,329 | 71,598 | 966,657 | Jul 02 |
| Greenman William Mariner | President and CEO | Jun 30 '26 | Sale | 2.94 | 101,919 | 299,937 | 5,053,036 | Jul 02 |
| Green Kevin Dennis | Chief Financial Officer | Jun 30 '26 | Sale | 2.94 | 33,676 | 99,105 | 1,062,188 | Jul 02 |
| BJERKHOLT ERIC | Director | Jun 09 '26 | Sale | 2.60 | 20,454 | 53,180 | 261,679 | Jun 11 |
| Jayaraman Vivek K | Chief Operating Officer | May 29 '26 | Sale | 3.00 | 16,667 | 50,001 | 1,656,707 | Jun 02 |
| Jayaraman Vivek K | Chief Operating Officer | May 01 '26 | Sale | 3.00 | 16,667 | 50,001 | 1,673,374 | May 05 |
| Jayaraman Vivek K | Chief Operating Officer | Mar 12 '26 | Sale | 1.66 | 165,200 | 273,769 | 1,747,674 | Mar 16 |
| Greenman William Mariner | President and CEO | Mar 12 '26 | Sale | 1.66 | 447,757 | 742,023 | 4,998,493 | Mar 16 |
| Green Kevin Dennis | Chief Financial Officer | Mar 12 '26 | Sale | 1.66 | 127,544 | 211,366 | 1,040,551 | Mar 16 |
| Benjamin Richard J | Chief Medical Officer | Mar 12 '26 | Sale | 1.66 | 101,740 | 168,604 | 777,361 | Mar 16 |
| Jensen Chrystal | Chief Legal Officer | Mar 12 '25 | Sale | 1.66 | 113,008 | 187,277 | 946,131 | Mar 16 |
| Benjamin Richard J | Chief Medical Officer | Mar 05 '26 | Sale | 2.06 | 122,466 | 252,604 | 943,762 | Mar 10 |